MISX:PRTK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Public Joint-Stock Company PROTEK, together with its subsidiaries, engages in the distribution and retail sale of pharmaceutical, health, and beauty products in Russia.


Snowflake Analysis

Excellent balance sheet and good value.

Share Price & News

How has PROTEK's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PRTK has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.6%

PRTK

3.9%

RU Healthcare

2.8%

RU Market


1 Year Return

8.3%

PRTK

0.9%

RU Healthcare

0.9%

RU Market

Return vs Industry: PRTK exceeded the Russian Healthcare industry which returned -0.2% over the past year.

Return vs Market: PRTK exceeded the Russian Market which returned 0.1% over the past year.


Shareholder returns

PRTKIndustryMarket
7 Day-0.6%3.9%2.8%
30 Day-0.7%8.8%4.4%
90 Day-1.5%-7.4%-13.6%
1 Year8.3%8.3%1.6%0.9%7.7%0.9%
3 Year0.4%-4.5%-17.9%-21.0%53.1%28.7%
5 Year230.3%144.1%-1.2%-6.7%115.8%68.5%

Price Volatility Vs. Market

How volatile is PROTEK's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PROTEK undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PRTK (RUB98) is trading below our estimate of fair value (RUB203.41)

Significantly Below Fair Value: PRTK is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PRTK is good value based on its PE Ratio (9.5x) compared to the Healthcare industry average (21.5x).

PE vs Market: PRTK is poor value based on its PE Ratio (9.5x) compared to the Russian market (8.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PRTK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PRTK is good value based on its PB Ratio (1.3x) compared to the XE Healthcare industry average (1.8x).


Next Steps

Future Growth

How is PROTEK forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PROTEK has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has PROTEK performed over the past 5 years?

-11.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PRTK has high quality earnings.

Growing Profit Margin: PRTK's current net profit margins (1.4%) are lower than last year (2.5%).


Past Earnings Growth Analysis

Earnings Trend: PRTK's earnings have declined by -11.7% per year over the past 5 years.

Accelerating Growth: PRTK's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PRTK had negative earnings growth (-40.5%) over the past year, making it difficult to compare to the Healthcare industry average (-2%).


Return on Equity

High ROE: PRTK's Return on Equity (9.1%) is considered low.


Next Steps

Financial Health

How is PROTEK's financial position?


Financial Position Analysis

Short Term Liabilities: PRTK's short term assets (RUB89.1B) exceed its short term liabilities (RUB81.0B).

Long Term Liabilities: PRTK's short term assets (RUB89.1B) exceed its long term liabilities (RUB21.8B).


Debt to Equity History and Analysis

Debt Level: PRTK's debt to equity ratio (7.7%) is considered satisfactory.

Reducing Debt: PRTK's debt to equity ratio has increased from 1.2% to 7.7% over the past 5 years.

Debt Coverage: PRTK's debt is well covered by operating cash flow (420.8%).

Interest Coverage: PRTK's interest payments on its debt are well covered by EBIT (3.5x coverage).


Balance Sheet


Next Steps

Dividend

What is PROTEK's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PRTK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PRTK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PRTK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PRTK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: PRTK is not paying a notable dividend for the Russian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PRTK's dividend in 3 years as they are not forecast to pay a notable one for the Russian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.1yrs

Average management tenure


CEO

Vadim Muzyaev (61yo)

no data

Tenure

Mr. Vadim Gennadyevich Muzyaev serves as the Chief Executive Officer at PROTEK Group. Mr. Muzyaev has been serving as President at PROTEK Group since 2002. Mr. Muzyaev serves as Deputy Chairman of PROTEK G ...


Leadership Team

NamePositionTenureCompensationOwnership
Vadim Yakunin
Founder and Chairman18.33yrsno data24.99% RUB12.6b
Vadim Muzyaev
Deputy Chairmanno datano datano data
Timofey Prokopov
CFO and VP of Finance & Investmentno datano datano data
Sergey Anoshin
Director of Legal Affaires and Member of Administrative Councilno datano datano data
Alexey Molchanov
General Director-CV Protekno datano datano data
Andrey Yegorova
General Directorno datano datano data
Aleksander Filippov
Chief Executive Officer of Rigla Pharmacy Chain8.58yrsno datano data
Dmitry Pogrebinsky
Chief Executive Officer of CV Protek6.08yrsno datano data
Vadim Yatsuk
Chief Executive Officer of ZAO Sotex PharmFirm5.33yrsno datano data

6.1yrs

Average Tenure

50yo

Average Age

Experienced Management: PRTK's management team is seasoned and experienced (6.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Vadim Yakunin
Founder and Chairman18.33yrsno data24.99% RUB12.6b
Vadim Muzyaev
Deputy Chairmanno datano datano data
Sergey Anoshin
Director of Legal Affaires and Member of Administrative Councilno datano datano data
Alexey Molchanov
General Director-CV Protekno datano datano data
Andrey Yegorova
General Directorno datano datano data
Leonid Sevast'Yanov
Independent Director10.42yrsno datano data
Vadim Gorbunov
Independent Director8.58yrsno datano data
Aleksandr Suhoruchenko
Independent Directorno datano datano data
Natalia Shchipletsova
Member of the Audit Committee no datano datano data
Sergey Guz
Independent Director4.83yrsno datano data

8.6yrs

Average Tenure

56yo

Average Age

Experienced Board: PRTK's board of directors are considered experienced (8.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Public Joint-Stock Company PROTEK's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Public Joint-Stock Company PROTEK
  • Ticker: PRTK
  • Exchange: MISX
  • Founded: 1990
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: ₽50.421b
  • Shares outstanding: 515.03m
  • Website: https://www.protek-group.ru

Number of Employees


Location

  • Public Joint-Stock Company PROTEK
  • Building 4
  • 22, Kashirskoye Shosse
  • Moscow
  • 115201
  • Russia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PRTKMISX (Micex - Rts)YesOrdinary SharesRURUBApr 2010

Biography

Public Joint-Stock Company PROTEK, together with its subsidiaries, engages in the distribution and retail sale of pharmaceutical, health, and beauty products in Russia. It operates through three segments: Distribution, Retail, and Production. The Distribution segment distributes a range of pharmaceuticals, health, and beauty products to medical facilities, independent pharmacies, pharmacy chains, and wholesalers. This segment also provides ePharma2 software that helps in the automation of inventory accounting for individual pharmacies and pharmacy chains; and contract manufacturing services for medicines, bandages, napkins, etc., as well as customs and warehouse processing of pharmaceutical products. The Retail segment retails pharmaceuticals, health, and beauty products through its pharmacies under the Rigla brand. The Production segment produces and sells pharmaceuticals to third parties. This segment offers medicines that are used for the treatment of cardiology, rheumatology, neurology, oncology, and nephrology, as well as for general purposes; and recombinant human erythropoietin, which is used for the treatment of various anaemias. The company also distributes raw materials for pharmaceuticals manufacturing, as well as provides financial intermediation services. Public Joint-Stock Company PROTEK was incorporated in 1990 and is based in Moscow, Russia. Public Joint-Stock Company PROTEK is a subsidiary of LLC PROTEK. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/25 22:22
End of Day Share Price2020/05/25 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.